{"id":412104,"date":"2024-06-07T00:00:00","date_gmt":"2024-06-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2024-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-constipation-including\/"},"modified":"2026-03-31T10:29:44","modified_gmt":"2026-03-31T10:29:44","slug":"algoim0056-2024-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-constipation-including","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0056-2024-biopharma-irritable-bowel-syndrome-treatment-algorithms-claims-data-analysis-ibs-constipation-including\/","title":{"rendered":"Irritable Bowel Syndrome | Treatment Algorithms: Claims Data Analysis | IBS-Constipation (Including IBS Without Diarrhea) | US | 2024"},"content":{"rendered":"<p>Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes: constipation-predominant, diarrhea-predominant, and mixed. ICD codes for IBS include a variety of subtypes; this analysis covers constipation-predominant IBS (IBS-C) and IBS without diarrhea. Limited treatment options are available, and only a few drugs have FDA approval for IBS-C. Current treatments include antidepressants (off-label), motor stimulants (off-label), anticholinergic agents (off-label), guanylate cyclase-C agonists (Allergan\u2019s Linzess and Synergy Pharmaceutical\u2019s Trulance), bicyclic fatty acids (Takeda\u2019s Amitiza and Par\u2019s generic lubiprostone), and sodium\/ hydrogen exchanger 3 (NHE3) inhibitors (Ardelyx\u2019s Ibsrela). These treatments are only moderately effective. Zelnorm, a 5-HT4 receptor agonist, was relaunched in 2019 for IBS-C in women younger than age 65 but was removed from the market again in 2022 for business-related reasons.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IBS-C (including IBS without diarrhea) patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IBS-C (including IBS without diarrhea) patients?<\/li>\n<li>How has Ibsrela been integrated into the treatment algorithm, and what is its source of business? Do Linzess, Trulance, and the newly launched generic lubiprostone continue to gain patient share?<\/li>\n<li>What percentage of IBS-C patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?<\/li>\n<li>What percentage of IBS-C patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>Treatment Algorithms: Claims Data Analysis<\/em> provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Allergan, Synergy Pharmaceuticals, Takeda, Alfasigma<\/p>\n<p><strong>Key drugs:<\/strong> Ibsrela, Linzess, Trulance, Amitiza, lubiprostone (generic), Zelnorm, dicyclomine, hyoscyamine sulphate \/ scopolamine, SSRIs, SNRIs, tricyclic antidepressants<\/p>\n<p><strong>SOLUTION ENHANCEMENT<\/strong><\/p>\n<p>The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.<\/p>\n","protected":false},"template":"","class_list":["post-412104","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-irritable-bowel-syndrome","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/412104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/412104\/revisions"}],"predecessor-version":[{"id":412452,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/412104\/revisions\/412452"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=412104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}